AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial

RTTNews | 1001 days ago
Stocktwits
AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial

(RTTNews) - Swiss biopharmaceutical company AC Immune SA (ACIU) announced Friday that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms.

ACI-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau). Studies have shown that pTau correlates with AD progression and the trial aims to show that ACI-35.030 can prevent or slow down the progression of tau pathology and onset of clinical symptoms.

Under the terms of the licensing agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson (JNJ) company, AC Immune will now receive a milestone payment of CHF 15 million and will receive another milestone payment of CHF 25 million related to achieving a non-disclosed enrollment target.

The partnership with Janssen aims to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other Tauopathies.

The Phase 2b ReTain trial is a potentially registration-enabling trial and is a randomized, multicenter, double-blind, placebo-controlled clinical study in participants with preclinical AD to assess the clinical effect of active immunization with ACI-35.030.

The Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease (AD).

Tags: JNJ ACIU
Stocktwits
read more
Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down

Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down

Drug major Johnson & Johnson, while reporting slightly lower second-quarter profit despite sales growth, on Wednesday raised again its earnings and sales forecast for fiscal 2026. The company also announced a quarterly dividend. In pre-market activity, the shares were losing around 1.9 percent.
RTTNews | 58 days ago
Johnson & Johnson Q1 Profit Down, Sales Rise; Lifts FY26 Outlook

Johnson & Johnson Q1 Profit Down, Sales Rise; Lifts FY26 Outlook

Drug major Johnson & Johnson (JNJ), while reporting sharply lower first-quarter profit despite sales growth, on Tuesday lifted fiscal 2026 earnings and sales forecast for fiscal 2026. The company also announced higher quarterly dividend. In pre-market activity, the shares were losing around 1.6 percent.
RTTNews | 150 days ago
Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast

Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast

Johnson & Johnson reported Wednesday weak profit in its second quarter on charges, while adjusted earnings beat market estimates on sales growth. The drug major further trimmed its fiscal 2024 adjusted earnings outlook, but lifted operational sales view to mainly reflect the acquisition of Shockwave Medical. In pre-market activity on the NYSE, Johnson & Johnson shares were losing around 0.5...
RTTNews | 786 days ago
Integra LifeSciences To Acquire Acclarent For $275 Mln Cash

Integra LifeSciences To Acquire Acclarent For $275 Mln Cash

Medical technology firm Integra LifeSciences Holdings Corp. (IART) announced Wednesday that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing. This is subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones.
RTTNews | 1003 days ago
Johnson & Johnson Guides FY24 Adj. EPS Below Estimates

Johnson & Johnson Guides FY24 Adj. EPS Below Estimates

Ahead of the meeting with the investment community at the New York Stock Exchange later on Tuesday, Johnson & Johnson (JNJ) initiated financial guidance for the full-year 2024 and for the long term.
RTTNews | 1011 days ago
Tools
Kalender Ekonomi
Jam pasar
Suku bunga
Kalender hari libur
Pasar Valas
Forex Volatility
Forex Correlation
Berita Forex
Analisis Forex
COT Data
Likuiditas
Kalkulator Forex
Forex Heat Map
Indikator ekonomi Konverter mata uang
Komunitas
Komunitas
Sistems
Most Popular Systems
Strategies
Kontes
Forex Charts
Forex Sentiment
Indikator Sentimen
Reviu
Pialang
Perusahaan Prop Trading
VPS Services
Signal Providers
EA Programming Services
Program Afiliasi
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Bursa Kripto
Kursus trading
Pelacak Portofolio Saham
Pialang
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions
Siaran Pers
Platform
Widget
Features
API
RSS
Stock Portfolio
Affiliate Software
Grafik Lanjutan
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2026 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.